How to deal with steroids use in the management of metastatic prostate cancer during pandemic
Transl Androl Urol
.
2020 Aug;9(4):1546-1549.
doi: 10.21037/tau-20-1011.
Authors
Michael Baboudjian
1
,
Guillaume Ploussard
2
,
Shahrokh F Shariat
3
4
,
Piet Ost
5
,
Alberto Briganti
6
,
Morgan Roupret
7
,
Benjamin Pradere
3
8
Affiliations
1
Department of Urology and Kidney Transplantation, Conception Academic Hospital, APHM, Aix-Marseille University, Marseille, France.
2
Department of Urology, Clinique La Croix du Sud, Quint-Fonsegrives, France.
3
Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
4
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
5
Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium.
6
Department of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
7
Department of Urology, Pitié-Salpêtrière Hospital, AP-HP, Predictive Onco-urology, GRC n°5, Sorbonne University, Paris, France.
8
Department of Urology, University Hospital of Tours, Tours, France.
PMID:
32944516
PMCID:
PMC7475678
DOI:
10.21037/tau-20-1011
No abstract available
Publication types
Editorial